Finally, this is the first study to demonstrate that serum FSTL3 level partially mediates the association of increased NAFLD fibrosis risk and AMI in patients with T2DM and co-existent NAFLD. Here, FSTL3 is linked to metabolic dysfunction-associated steatotic liver disease.